Vol. 2 No. 4 (2022)
Reimbursement Reviews

Estradiol and Progesterone (Bijuva)

Published April 8, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses estrogen-progestogen (Bijuva) in oral capsules, 0.5 mg estradiol (as estradiol hemihydrate)/100 mg progesterone and 1 mg estradiol (as estradiol hemihydrate)/100 mg progesterone.
  • Indication: For the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus.